In the search for newer and advanced methods for the detection of cancer, quicker and non-invasive techniques are imperative. One such potential approach for detection is the detection of oncogenes in the suspected tumour tissues. This search has led to the identification of the oncogene SHh, which is a key influencer in the tumourigenic pathways. Therefore, a cancer detection method, which would target the identification of the oncogene SHh would therefore be a step forward in the advancement of cancer research.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.mehy.2019.109534 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A novel dominant-negative variant of IRF8 in a mother and son: Clinical, phenotypic and biological characteristics.
J Allergy Clin Immunol
March 2025
Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minn. Electronic address:
Background: The few reported patients with pathogenic IRF8 variants have manifested 2 distinct phenotypes: (1) an autosomal recessive severe immunodeficiency with significant neutrophilia and absence of or significant decrease in monocytes and dendritic cells and (2) a dominant-negative form with only a decrease in conventional type 2 dendritic cells (cDC2s) and susceptibility to mycobacterial disease.
Objectives: Genetic testing of a child with persistent EBV viremia identified a novel IRF8 variant: c.1279dupT (p.
Update on Cancer Screening Recommendations for Individuals with Li-Fraumeni Syndrome.
Clin Cancer Res
March 2025
Hospital for Sick Children, Toronto, Ontario, Canada.
Li-Fraumeni syndrome (LFS) is an autosomal dominant cancer predisposition condition characterized by a high lifetime risk for a wide spectrum of malignancies associated with germline pathogenic/likely pathogenic (P/LP) variants in the TP53 tumor suppressor gene. Secondary malignant neoplasms are particularly common. Early cancer detection through surveillance enables early intervention and leads to improved clinical outcomes with reduced tumor-related mortality and treatment-related morbidity.
View Article and Find Full Text PDFValidation of Diagnostic Utility of Washout CYFRA 21-1 in Lymph Node Metastasis of Thyroid Cancer.
Clin Cancer Res
March 2025
Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea, Seoul, Korea (South), Republic of.
Purpose: Traditional methods, fine-needle aspiration cytology (FNAC) and washout thyroglobulin (Tg), do not always provide sufficient accuracy for diagnosing lymph node (LN) metastasis in thyroid cancer. This study aimed to validate the diagnostic performance of washout cytokeratin fragment 21-1 (CYFRA 21-1) as a complementary biomarker for diagnosing metastatic LNs in thyroid cancer and to explore its relationship with molecular analysis and distant metastasis.
Patients And Methods: In this retrospective cohort study involving 230 LNs in 224 patients with PTC, FNAC, washout Tg, and CYFRA 21-1 levels were measured in suspicious LNs.
Leading designs of peptide-based chemical probes for medical imaging- the dawn of precision diagnostics.
Future Med Chem
March 2025
Department of Drug and Health Sciences, University of Catania, Catania, Italy.
External Testing of a Commercial AI Algorithm for Breast Cancer Detection at Screening Mammography.
Radiol Artif Intell
March 2025
Department of Medical Physics, BC Cancer-Kelowna, 399 Royal Ave, Kelowna, BC, Canada V1Y 5L3.
Purpose To test a commercial artificial intelligence (AI) system for breast cancer detection at the BC Cancer Breast Screening Program. Materials and Methods In this retrospective study of 136,700 women (age: µ = 58.8, σ = 9.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!